Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 1/2 1

Status

Unknown 6Not yet recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Thoracic 6

Conditions

Carcinoma, Non-Small-Cell Lung 26Small Cell Lung Carcinoma 10Breast Neoplasms 8Sarcoma 7Carcinoma, Hepatocellular 7Lung Neoplasms 6Stomach Neoplasms 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Esophageal Squamous Cell Carcinoma 4Carcinoma 4Non-squamous Non-small Cell Lung Cancer 3NSCLC 3Glioma 3Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Thyroid Neoplasms 2Pheochromocytoma 2Paraganglioma 2Neoplasms 2Liver Neoplasms 2Gynecological Cancer 2Extensive Stage Small Cell Lung Cancer 2Esophageal Neoplasms 2Endometrial Neoplasms 2Digestive System Neoplasms 2Carcinoma, Ovarian Epithelial 2Advanced Solid Tumor 2Squamous Non-small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Cisplatin 38Carboplatin 28Gemcitabine 23Docetaxel 20Radiotherapy 18Etoposide 15Paclitaxel 13Erlotinib Hydrochloride 13Vinorelbine 11Drug Therapy 11pembrolizumab 9aumolertinib 9apatinib 9Pemetrexed 9Gefitinib 9osimertinib 7endostar protein 7Thoracic Surgery, Video-Assisted 7Blood Specimen Collection 7camrelizumab 6anlotinib 6Vinblastine 6Surgical Procedures, Operative 6sintilimab 5Radiosurgery 5Fluorodeoxyglucose F18 5Cyclophosphamide 5Bevacizumab 5durvalumab 4Mitomycin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Unknown × Lung Neoplasms × anlotinib × Clear all
NCT05319886 2022-05-20

AP

The First Affiliated Hospital of Xinxiang Medical College

Unknown
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04731909 2021-02-10

Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer

Third Military Medical University

Phase NA Unknown
80 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT03983928 2019-08-15

Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Unknown
30 enrolled
Thoracic

Lung Neoplasms

NCT03780283 2018-12-21

Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC

First Hospital of Shijiazhuang City

Phase 2 Unknown
30 enrolled
Thoracic

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03765775 2018-12-06

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

First Hospital of Shijiazhuang City

Phase 2 Unknown
20 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03589950 2018-07-18

Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer

The First People's Hospital of Lianyungang

Phase 2 Unknown
60 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡